用于预测严重孕产妇疾病的扩展产科合并症评分系统
该研究利用2016-2017年加利福尼亚州分娩住院出院数据开发并验证扩展产科合并症评分,共纳入919,546例分娩,严重孕产妇疾病发生率为168/10,000,非输血严重孕产妇疾病发生率为74/10,000;评分在加州和国家数据集中C统计量为0.78和0.84(加州)及0.82和0.87(全国),优于既往产科合并症指数。
要点
- 扩展产科合并症评分基于27个患者层面危险因素开发,用于预测严重孕产妇疾病。
- 胎盘植入谱系疾病风险最高,严重孕产妇疾病aRR为30.5,非输血严重孕产妇疾病aRR为54.7。
- 评分在加州和国家数据集中区分度良好,C统计量分别为0.78/0.84和0.82/0.87。
核心结论
- 开发并验证了扩展产科合并症评分,以改善不同合并症病例组合患者人群间严重孕产妇疾病发生率的比较。
研究设计与样本
- 利用2016-2017年加利福尼亚州分娩住院出院数据开发评分,并在加州和国家数据集中验证。
- 纳入919,546例分娩,选取27个患者层面危险因素,采用靶向因果推断方法结合机器学习排序。
主要发现
- 严重孕产妇疾病发生率为168/10,000,非输血严重孕产妇疾病发生率为74/10,000。
- 胎盘植入谱系疾病风险最高,严重孕产妇疾病aRR为30.5,非输血严重孕产妇疾病aRR为54.7;妊娠期糖尿病风险最低,aRR分别为1.06和1.12。
- 基于aRR的归一化评分范围为严重孕产妇疾病1至59分,非输血严重孕产妇疾病1至36分。
- 加州数据集中C统计量为严重孕产妇疾病0.78、非输血严重孕产妇疾病0.84;国家数据集中分别为0.82和0.87。
- 校准图显示预测风险与实际风险一致性良好。
关键数值与推荐
- 严重孕产妇疾病定义采用美国疾病控制与预防中心指数,非输血严重孕产妇疾病排除仅输血为唯一指标的病例。
- 风险因素使用国际疾病分类第十版临床修改诊断代码识别。
临床怎么用
- 该评分可用于不同患者人群间严重孕产妇疾病发生率的比较。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and validate an expanded obstetric comorbidity score for predicting severe maternal morbidity that can be applied consistently across contemporary U.S. patient discharge data sets. METHODS: Discharge data from birth hospitalizations in California during 2016-2017 were used to develop the score. The outcomes were severe maternal morbidity, defined using the Centers for Disease Control and Prevention index, and nontransfusion severe maternal morbidity (excluding cases where transfusion was the only indicator of severe maternal morbidity). We selected 27 potential patient-level risk factors for severe maternal morbidity, identified using International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis codes. We used a targeted causal inference approach integrated with machine learning to rank the risk factors based on adjusted risk ratios (aRRs). We used these results to assign scores to each comorbidity, which sum to a single numeric score. We validated the score in California and national data sets and compared the performance to that of a previously developed obstetric comorbidity index. RESULTS: Among 919,546 births, the rates of severe maternal morbidity and nontransfusion severe maternal morbidity were 168 and 74 per 10,000 births, respectively. The highest risk comorbidity was placenta accreta spectrum (aRR of 30.5 for severe maternal morbidity and 54.7 for nontransfusion severe maternal morbidity) and the lowest was gestational diabetes mellitus (aRR of 1.06 for severe maternal morbidity and 1.12 for nontransfusion severe maternal morbidity). Normalized scores based on the aRR were developed for each comorbidity, which ranged from 1 to 59 points for severe maternal morbidity and from 1 to 36 points for nontransfusion severe maternal morbidity. The overall performance of the expanded comorbidity scores was good (C-statistics were 0.78 for severe maternal morbidity and 0.84 for nontransfusion severe maternal morbidity in California data and 0.82 and 0.87, respectively, in national data) and improved on prior comorbidity indices developed for obstetric populations. Calibration plots showed good concordance between predicted and actual risks of the outcomes. CONCLUSION: We developed and validated an expanded obstetric comorbidity score to improve comparisons of severe maternal morbidity rates across patient populations with different comorbidity case mixes.
引用
- Leonard SA, Kennedy CJ, Carmichael SL, et al. An Expanded Obstetric Comorbidity Scoring System for Predicting Severe Maternal Morbidity. Obstet Gynecol. 2020. PMID: 32769656. doi:10.1097/AOG.0000000000004022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。